Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia

Poulet, Emmanuel; Brunelin, Jérôme; Bediou, Benoît; Bation, Rémy; Forgeard, Louis; Daléry, J; d’Amato, Thierry; Saoud, Mohamed

doi:10.1016/j.biopsych.2004.10.007

Cited by 155 publications

(99 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poulet and colleagues 129 treated people for 5 days and found after 8 weeks half of the rTMS participants continued to have a >20% decrease in auditory hallucinations. None of those randomized to sham treatment responded to treatment.…”

Section: Rtms For the Treatment Of Schizophreniamentioning

confidence: 99%

“…Rosa and colleagues did not find a significant group difference between active and sham rTMS treatment over time, but those receiving rTMS continued to show improvement in symptoms 4 weeks after treatment had stopped, whereas sham-treated participants did not continue to improve. 129 Hoffman and colleagues 128 reported that the mean survivorship interval for the 45 persons receiving either masked or unmasked active rTMS was 13 weeks post-trial. Nonsurvivorship was defined as a return of hallucination severity to 80% of pretrial levels, increase in antipsychotic drug dose, or change in antipsychotic drug.…”

Section: Rtms For the Treatment Of Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

Boyer

Kreyenbuhl

Kelly

et al. 2009

Schizophrenia Bulletin

825

537

View full text Add to dashboard Cite

Section: Rtms For the Treatment Of Schizophreniamentioning

confidence: 99%

Section: Rtms For the Treatment Of Schizophreniamentioning

confidence: 99%

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

Boyer

Kreyenbuhl

Kelly

et al. 2009

Schizophrenia Bulletin

825

537

View full text Add to dashboard Cite

“…Improvement in auditory hallucinations after stimulation of the left temporal-parietal cortex augmenting antipsychotic treatment was observed in two randomised, double-blind, sham (placebo)-controlled trials and in one randomised, double-blind, cross-over study, each with small sample sizes (Hoffman et al 2000;Hoffman et al 2003;Poulet et al 2005). Two other randomised, sham-controlled trials could not confirm these positive results, and found no significant differences between sham and verum stimulation (McIntosh et al 2004;Schoenfeldt-Lecuona et al 2004).…”

Section: Repetitive Transcranial Magnetic Stimulation (Rtms)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

“…The site of stimulation was left temporoparietal area, daily 15-20 min session with frequency of 1 HZ for 5-10 days, intensity ranging 80-100% of motor threshold. However, there were some studies with different protocols and over the different sites of stimulation including daily two sessions [47,48] and stimulating left auditory cortex. [49] There are also some studies that have failed to significantly improve the auditory-verbal hallucinations or with low improvements.…”

Section: Rtms For Hallucinationsmentioning

confidence: 99%

Untitled

Rashidi

2017

AJP

View full text Add to dashboard Cite

Psychiatric disorders are the most common debilitating diseases worldwide. Repetitive transcranial magnetic stimulation (rTMS) has shown therapeutic outcomes in different neurophysiology and neuropsychiatric disorders. Despite controversial findings on the therapeutic outcomes of this technique in different psychiatric disorders, researchers emphasize on developing this technique as an alternative or adjunctive modality for these disorders. Depression, different hallucinations, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and substance abuse are the main disorders have shown good treatment response to rTMS. This study aims to comprehensively overview the applications and recent advances in rTMS applications in psychiatric disorders. The databases of PubMed (1985PubMed ( -2017, Web of Sciences (1985-2017, Embase (1985-2017), Cochrane Central Library (1985-2017), and Google Scholar (1985-2017 were searched using the keywords of repetitive transcranial magnetic stimulation OR rTMS AND psychiatric disorders AND treatment. The retrieved records were reviewed, and the relevant studies were selected for further review. Repeated sessions of low frequency (≤5 Hz) rTMS induce long-lasting neural inhibition or depotentiation, whereas high frequency (>5 Hz) induces long-lasting neural excitability or potentiation. Depending on the neural alteration induced by a disorder, low-or high-frequency rTMS is used for the treatment. The rTMS is approved as acute treatment for major depression. The other diseases with promising outcomes are different hallucinations, OCD, and PTSD. rTMS seems to be an alternative or adjunctive therapeutic modality in different psychiatric disorders. To reach efficient clinical application for each disorder, further randomized clinical trials, as well as preclinical studies, are needed.

show abstract

Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia

Cited by 155 publications

References 26 publications

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Untitled

Contact Info

Product

Resources

About